Service of Neumology, Lung Transplantation Unit, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Transplant Coordination Unit & Service of Intensive Care, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
Am J Transplant. 2022 Jul;22(7):1852-1860. doi: 10.1111/ajt.17057. Epub 2022 Apr 18.
Despite the benefits of abdominal normothermic regional perfusion (A-NRP) for abdominal grafts in controlled donation after circulatory death (cDCD), there is limited information on the effect of A-NRP on the quality of the cDCD lungs. We aimed to study the effect of A-NRP in lungs obtained from cDCD and its impact on recipients´ outcomes. This is a study comparing outcomes of lung transplants (LT) from cDCD donors (September 2014 to December 2021) obtained using A-NRP as the abdominal preservation method. As controls, all lung recipients transplanted from donors after brain death (DBD) were considered. The primary outcomes were lung recipient 3-month, 1-year, and 5-year survival. A total of 269 LT were performed (60 cDCD and 209 DBD). There was no difference in survival at 3 months (98.3% cDCD vs. 93.7% DBD), 1 year (90.9% vs. 87.2%), and 5 years (68.7% vs. 69%). LT from the cDCD group had a higher rate of primary graft dysfunction grade 3 at 72 h (10% vs. 3.4%; p < .001). This is the largest experience ever reported with the use of A-NRP combined with lung retrieval in cDCD donors. This combined method is safe for lung grafts presenting short-term survival outcomes equivalent to those transplanted through DBD.
尽管腹部亚常温区域灌注(A-NRP)对控制下的循环死亡后供体(cDCD)腹部移植物有益,但关于 A-NRP 对 cDCD 肺质量影响的信息有限。我们旨在研究 A-NRP 对从 cDCD 获得的肺的影响及其对受者结局的影响。这是一项比较使用 A-NRP 作为腹部保存方法获得的 cDCD 供体肺移植(LT)与脑死亡(DBD)供体移植的肺受体 3 个月、1 年和 5 年生存率的研究。作为对照,考虑了所有从 DBD 供体移植的肺受体。主要结局是肺受体 3 个月、1 年和 5 年生存率。共进行了 269 例 LT(60 例 cDCD 和 209 例 DBD)。3 个月(98.3% cDCD 与 93.7% DBD)、1 年(90.9% 与 87.2%)和 5 年(68.7% 与 69%)的生存率无差异。cDCD 组在 72 小时原发性移植物功能障碍 3 级的发生率更高(10%与 3.4%;p < 0.001)。这是迄今为止使用 A-NRP 联合肺获取在 cDCD 供体中报告的最大经验。这种联合方法对肺移植物是安全的,短期生存结果与通过 DBD 移植的结果相当。